Cancer News: Breast
Recent findings show that higher consumption of grilled, barbequed, and smoked meat may increase the mortality risk among breast cancer survivors.
The US FDA approved a new treatment for hormone-receptor positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.
A study showed that a higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 than it is in older patients.
Fewer women with history of breast and ovarian cancer take a recommended genetic test. This may increase their risk for additional cancers in the future.
Fulvestrant has been approved by the FDA for broader use in hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
Breast cancer patients aged 65+ reported being more satisfied long term with the cosmetic outcomes of less radiation. However, this should be balanced with a slightly higher recurrence risk.
Adding pertuzumab to a standard regimen for hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer improved progression-free survival in a clinical trial.
In a clinical trial, women diagnosed with stage 1 or 2 breast cancer used a scalp-cooling system while undergoing chemotherapy. The results show that it helped them prevent hair loss.
Adding veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate among patients with locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations.
Adding everolimus to fulvestrant more than doubled progression-free survival for women with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy.
Buparlisib, in combination with fulvestrant endocrine therapy, improved outcomes for patients with hormone (HR)-positive advanced breast cancer after treatment with everolimus plus exemestane.
Many breast cancer patients will consider breast reconstruction after mastectomy. Radiation therapy can alter the tissue around the breast, impacting reconstruction efforts.
Progression-free survival doubled in patients with aromatase inhibitor-resistant metastatic breast cancer treated with everolimus plus fulvestrant vs fulvestrant alone.
Older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women without much higher risk for complications.
Breast cancer patients with high vitamin D levels in the blood may have less dangerous tumors and better outcomes. This is according to research within an ongoing study.
Palbociclib is now approved in Europe for the treatment of women with hormone receptor-positive, HER2-negative (HR+/HER2-), locally advanced or metastatic breast cancer.
Women who have a history of depression may have worse survival outcomes, compared to patients without past mental health challenges. This is based on Danish research.
Adding palbociclib to letrozole for the treatment of estrogen receptor positive (ER+), HER2-negative (HER2-) advanced breast cancer increased progression-free survival from 14.5 to over 25 months.
Emerging research seems to indicate that women who had breast cancer and maintain a normal weight have lower risk of the cancer coming back.
Precision medicine test in cancer care helps patients and doctors decide if chemotherapy is the proper treatment and what side effects will occur.
Ribociclib (CDK4/6 inhibitor) combined with letrozole improves by 44% the progression-free survival in postmenopausal women with hormone receptor positive advanced breast cancer.
Fulvestrant increases progression-free survival (PFS) in hormone receptor positive (ER+) advanced breast cancer patients.
Immediate breast reconstruction (IBR) after mastectomy causes fewer breast cancer psychological side-effects, compared to delayed breast reconstruction (DBR).
Treating recurrent breast cancer with a 2nd lumpectomy and partial breast irradiation brings better results compared to conventional breast surgery.
A supplemental "boost" of radiation may reduce breast cancer recurrence in Ductal Carcinoma in Situ (DCIS) patients.
An expert panel issued recommendations on post-mastectomy radiation therapy for breast cancer patients, calling for careful counseling and clinical judgement.
Half of female breast cancer survivors may suffer from chemo brain, a genuine consequence of chemotherapy. Study tries to find how long it is likely to last.
Obesity and smoking were associated with higher risk of developing cardiotoxicity after treatment in breast cancer patients, clinical studies reveal.
Patients undergoing chemotherapy experienced no nausea or vomiting after including olanzapine to their prophylactic drug combination, a phase 3 study reveals.
A new analysis shows that cutting of sensory nerves during breast cancer surgery is connected with post-surgical chronic pain.